Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 7:41 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 865–888 of 8,037 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: RNA Clear all
Completed Phase 1Phase 2 Interventional Results available

Study in Participants With Early Stage Coronavirus Disease 2019 (COVID-19) to Evaluate the Safety, Efficacy, and Pharmacokinetics of Remdesivir Administered by Inhalation

NCT04539262
View directory record Official record
Conditions
COVID-19
Interventions
Remdesivir (RDV), Placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
156 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
28
States / cities
Mesa, Arizona • Tucson, Arizona • Bakersfield, California + 20 more
Source: ClinicalTrials.gov public record
Updated Mar 3, 2022 · Synced Oct 30, 2026, 7:41 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Genetic Factors and Interrelationships for Sexual Orientation, Susceptibility to HIV and Kaposi's Sarcoma, Alcoholism and Psychological Traits, and Histocompatibility Antigens

NCT00001294
View directory record Official record
Conditions
Alcoholism, HIV Infection, Homosexuality, Kaposi's Sarcoma
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Not listed
Enrollment
2,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1992 – 2005
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 30, 2026, 7:41 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Assess Safety and Immunogenicity of A/H5 Inactivated Monovalent Influenza Vaccines at Different Antigen Dose Levels Adjuvanted With AS03 or MF59

NCT06560151
View directory record Official record
Conditions
Influenza
Interventions
3.75 µg H5N8 antigen plus full dose AS03A, 7.5 µg H5N8 antigen plus full dose AS03A, 15 µg H5N8 antigen plus full dose AS03A, 3.75 µg H5N8 antigen plus half dose AS03A, 7.5 µg H5N8 antigen plus half dose AS03A, 15 µg H5N8 antigen plus half dose AS03A, 3.75 µg H5N8 antigen plus MF59, 7.5 µg H5N8 antigen plus MF59, 15 µg H5N8 antigen plus MF59, 3.75 µg H5N1 antigen plus full dose AS03A, 7.5 µg H5N1 antigen plus full dose AS03A, 15 µg H5N1 antigen plus full dose AS03A, 3.75 µg H5N1 antigen plus MF59, 7.5 µg H5N1 antigen plus MF59, 15 µg H5N1 antigen plus MF59
Biological
Lead sponsor
Biomedical Advanced Research and Development Authority
Federal
Eligibility
18 Years and older
Enrollment
1,380 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
20
States / cities
Atlanta, Georgia • Savannah, Georgia • Oak Lawn, Illinois + 17 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 30, 2026, 7:41 PM EDT
Not listed Phase 2 Interventional

Bisphosphonate Therapy for HIV-Infected Adults With Decreased Bone Mineral Density

NCT00102908
View directory record Official record
Conditions
HIV Infections, Osteopenia, Osteoporosis
Interventions
Zoledronate, Zoledronate placebo
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 70 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Sep 26, 2008 · Synced Oct 30, 2026, 7:41 PM EDT
Terminated Phase 3 Interventional

Study Of Chemokine Coreceptor 5 (CCR5) Antagonist GW873140 In R5/X4-Tropic Treatment-Experienced HIV-Infected Subjects

NCT00197197
View directory record Official record
Conditions
HIV Infection
Interventions
GW873140
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005
U.S. locations
11
States / cities
Los Angeles, California • Norwalk, Connecticut • Fort Lauderdale, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Mar 29, 2011 · Synced Oct 30, 2026, 7:41 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Feasibility and Pilot Efficacy of Flash-heated Breast Milk to Reduce Maternal-to-Child-Transmission of HIV in Tanzania

NCT00523510
View directory record Official record
Conditions
HIV Infections
Interventions
Infant feeding counseling that includes Flash-heat
Procedure
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older · Female only
Enrollment
144 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Feb 14, 2012 · Synced Oct 30, 2026, 7:41 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Feasibility of Short-Term PrEP Uptake for MSM With Episodic High-Risk for HIV

NCT02495779
View directory record Official record
Conditions
Human Immunodeficiency Virus
Interventions
emtricitabine/tenofovir, CBT-based counseling
Drug · Behavioral
Lead sponsor
James Egan
Other
Eligibility
18 Years and older · Male only
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
2
States / cities
Boston, Massachusetts • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 27, 2019 · Synced Oct 30, 2026, 7:41 PM EDT
Completed Phase 1 Interventional

A Study of Zidovudine Plus Interleukin-2 in HIV-Infected Patients Who Have No Symptoms of Infection But Who Have Tender Lymph Nodes

NCT00001005
View directory record Official record
Conditions
HIV Infections
Interventions
Zidovudine, Aldesleukin
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1995
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 4, 2021 · Synced Oct 30, 2026, 7:41 PM EDT
Enrolling by invitation No phase listed Observational

Real-world Effectiveness of HPV Vaccine in Women Living With HIV and Its Impact on Cervical Cancer Screening Accuracies

NCT06144229
View directory record Official record
Conditions
Hiv, Hpv
Interventions
Self-Collection HPV testing kit from Abbott
Diagnostic Test
Lead sponsor
University of California, Los Angeles
Other
Eligibility
21 Years to 40 Years · Female only
Enrollment
650 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
9
States / cities
Denver, Colorado • Miami, Florida • Chicago, Illinois + 5 more
Source: ClinicalTrials.gov public record
Updated May 18, 2026 · Synced Oct 30, 2026, 7:41 PM EDT
Recruiting Phase 2Phase 3 Interventional

A Clinical Study of Islatravir and Ulonivirine for People With HIV-1 Who Have Not Been Treated Before (MK-8591B-062)

NCT07266831
View directory record Official record
Conditions
Human Immunodeficiency Virus Type 1 (HIV-1) Infection
Interventions
ISL, ULO, BIC/FTC/TAF, Placebo for BIC/FTC/TAF, Placebo to ISL/ULO, ISL/ULO
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
570 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
24
States / cities
Los Angeles, California • Denver, Colorado • Washington D.C., District of Columbia + 20 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 30, 2026, 7:41 PM EDT
Completed Not applicable Interventional

Blood Levels of Abacavir in HIV Infected Adolescents

NCT00087945
View directory record Official record
Conditions
HIV Infections
Interventions
Abacavir sulfate, Abacavir sulfate, lamivudine, and zidovudine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years to 25 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004
U.S. locations
19
States / cities
Alhambra, California • Los Angeles, California • San Diego, California + 15 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2013 · Synced Oct 30, 2026, 7:41 PM EDT
Recruiting Phase 4 Interventional

REINItiation of Antiretroviral Therapy Using Oral bicTegravir, emtrIcitAbine and Tenofovir alafenamidE

NCT07476339
View directory record Official record
Conditions
HIV -1 Infection, HIV (Human Immunodeficiency Virus), HIV, HIV 1 Infection
Interventions
Bictegravir, emtricitabine, and tenofovir alafenamide
Drug
Lead sponsor
CAN Community Health
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
10
States / cities
Clearwater, Florida • Ft. Pierce, Florida • Jacksonville, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Oct 30, 2026, 7:41 PM EDT
Completed Phase 1 Interventional

A Study of DPC 817 in HIV-Infected Males

NCT00040274
View directory record Official record
Conditions
HIV Infections
Interventions
DPC 817
Drug
Lead sponsor
Pharmasset
Industry
Eligibility
18 Years to 55 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 19, 2005 · Synced Oct 30, 2026, 7:41 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Safer Sex Program for Young African-American Men

NCT01439503
View directory record Official record
Conditions
Gonorrhea, Chlamydia, Trichomoniasis, Syphilis, HIV Infections
Interventions
Intervention
Behavioral
Lead sponsor
Richard Crosby
Other
Eligibility
15 Years to 29 Years · Male only
Enrollment
620 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2018
U.S. locations
1
States / cities
Jackson, Mississippi
Source: ClinicalTrials.gov public record
Updated Feb 21, 2019 · Synced Oct 30, 2026, 7:41 PM EDT
Completed Phase 1 Interventional

Drug Interactions Among Anti-HIV Agents

NCT00001766
View directory record Official record
Conditions
HIV Infection
Interventions
Amprenavir, Efavirenz, Abacavir, Nelfinavir, Ritonavir
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Not listed
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2003
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 30, 2026, 7:41 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Immune Response to a Live-Attenuated Respiratory Syncytial Virus (RSV) Vaccine in RSV-Seronegative Infants and Children

NCT02040831
View directory record Official record
Conditions
Respiratory Syncytial Virus Infections
Interventions
RSV LID ΔM2-2 Vaccine, Placebo Vaccine
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
6 Months to 24 Months
Enrollment
3 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 21, 2016 · Synced Oct 30, 2026, 7:41 PM EDT
Completed No phase listed Observational

Safety and Survival of Genetically Modified White Blood Cells in HIV-Infected Persons - A Study in Identical Twin Pairs

NCT00001353
View directory record Official record
Conditions
Acquired Immunodeficiency Syndrome, HIV Infection
Interventions
Genetically Marked Syngeneic T Lymphocytes
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Not listed
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1993 – 2002
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 30, 2026, 7:41 PM EDT
Completed Not applicable Interventional

Supporting Health Behavior Among Persons Living With HIV Using Tech, MOST, and Behavioral Economics

NCT04518241
View directory record Official record
Conditions
HIV Seropositivity, Adherence, Medication
Interventions
MI sessions, TMQQ, Type of compensation
Behavioral
Lead sponsor
New York University
Other
Eligibility
18 Years to 65 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 1, 2022 · Synced Oct 30, 2026, 7:41 PM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

Injectable Cabotegravir Compared to TDF/FTC For PrEP in HIV-Uninfected Men and Transgender Women Who Have Sex With Men

NCT02720094
View directory record Official record
Conditions
HIV Infections
Interventions
Cabotegravir Oral Tablet, TDF/FTC tablets, Placebo for TDF/FTC tablets, Placebo for cabotegravir oral tablet, CAB LA, Placebo for CAB LA
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
4,570 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2025
U.S. locations
27
States / cities
Birmingham, Alabama • Los Angeles, California • Oakland, California + 20 more
Source: ClinicalTrials.gov public record
Updated Mar 19, 2026 · Synced Oct 30, 2026, 7:41 PM EDT
Completed No phase listed Observational

Natural History of Systemic and Nasal Mucosal Immunity After Influenza Vaccination in a Pediatric Population

NCT04963166
View directory record Official record
Conditions
Influenza Immunity
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
2 Years to 17 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 8, 2026 · Synced Oct 30, 2026, 7:41 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Putative Investigational Therapeutics in the Treatment of Patients With Known Ebola Infection

NCT02363322
View directory record Official record
Conditions
Ebola Virus Infection
Interventions
B/Current Standard of Care Plus ZMapp, A/Current Standard of Care Alone
Drug · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Not listed
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 5, 2019 · Synced Oct 30, 2026, 7:41 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Safety/Immunogenicity/Genetic Drift of MP-12 Rift Valley Fever Vaccine

NCT00415051
View directory record Official record
Conditions
Rift Valley Fever
Interventions
RVF MP-12
Biological
Lead sponsor
U.S. Army Medical Research and Development Command
Federal
Eligibility
18 Years to 50 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2009
U.S. locations
1
States / cities
Fort Deterick, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 3, 2020 · Synced Oct 30, 2026, 7:41 PM EDT
Completed Phase 2 Interventional

Expanding the Pool in Orthotopic Heart Transplantation

NCT03222531
View directory record Official record
Conditions
Hepatitis C, Heart Transplant, Cardiac Transplant
Interventions
sofosbuvir/velpatasvir
Drug
Lead sponsor
Mary E. Keebler, MD
Other
Eligibility
18 Years to 71 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 22, 2026 · Synced Oct 30, 2026, 7:41 PM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Commercially Available Cannabis Products for Immune Support

NCT05944705
View directory record Official record
Conditions
Influenza, COVID-19, Common Cold
Interventions
Immune Support Supplement
Dietary Supplement
Lead sponsor
Center For Interventional Pain and Spine
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Bryn Mawr, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 29, 2024 · Synced Oct 30, 2026, 7:41 PM EDT